The collaboration will focus on developing a localized and sustained-release drug delivery system for oncology patients
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
This was a pre-approval inspection to cover our Oncology Injectable drug products for which ANDAs were filed with USFDA
This newly launched institute will be the centre of excellence in the treatment of all cancers under a single roof.
Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Subscribe To Our Newsletter & Stay Updated
